84.02
前日終値:
$82.27
開ける:
$82.78
24時間の取引高:
1.23M
Relative Volume:
1.27
時価総額:
$6.72B
収益:
$58.89M
当期純損益:
$-240.88M
株価収益率:
-27.10
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
+10.64%
1か月 パフォーマンス:
+14.95%
6か月 パフォーマンス:
+110.73%
1年 パフォーマンス:
+139.03%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc
|
84.02 | 6.58B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 再開されました | Guggenheim | Buy |
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera at Guggenheim Biotech Summit: Exploring Oral Drug Potential By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Candriam S.C.A. - MarketBeat
Certain Warrants of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Common Stock of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
CEO Moves: Will FATN outperform small cap indexesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - baoquankhu1.vn
Kymera Therapeutics (KYMR) Is Up 7.0% After Advancing Dual Phase 2b Trials for KT-621 - Sahm
Smart Money: What are Kymera Therapeutics Incs earnings expectationsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
KYMR initiates dosing in mid-stage asthma study of lead candidate - MSN
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - Investing News Network
Kymera Therapeutics (KYMR): A Biotech Stock with 54% Potential Upside Amid Innovative Protein Degradation Focus - DirectorsTalk Interviews
(KYMR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings) - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate - Yahoo Finance
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader By Investing.com - Investing.com South Africa
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader - Investing.com India
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader - TradingView
Analyst Barclays Raises Price Target for Kymera Therapeutics (KY - GuruFocus
Aug Movers: Can Kymera Therapeutics Inc benefit from deglobalization2025 Fundamental Recap & Weekly Breakout Watchlists - baoquankhu1.vn
Kymera Therapeutics (KYMR) Stock Analysis: Exploring A 64% Upside Potential - DirectorsTalk Interviews
What is the earnings history of Kymera Therapeutics Inc.2025 Trading Recap & Reliable Price Breakout Signals - mfd.ru
Responsive Playbooks and the KYMR Inflection - Stock Traders Daily
Aug Volume: What is the long term forecast for Kymera Therapeutics Inc stockWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Assessing Kymera Therapeutics (KYMR) Valuation After Milestone Updates For KT-621 And Partnered IRAK4 Programs - Sahm
Is BRID stock overvalued or fairly pricedJuly 2025 Sentiment & Community Trade Idea Sharing Platform - baoquankhu1.vn
Kymera Therapeutics director Esposito sells $373k in shares By Investing.com - Investing.com Nigeria
Kymera Therapeutics director Esposito sells $373k in shares - Investing.com
This drugmaker's stock is soaring over 40% Monday - MSN
Signal Recap: Does Loop Industries Inc outperform in volatile marketsMarket Activity Report & Safe Swing Trade Setups - baoquankhu1.vn
Exit Recap: Can Kymera Therapeutics Inc benefit from deglobalizationJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Portfolio Update: What is Kymera Therapeutics Incs 5 year growth outlookWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN
Is Kymera Therapeutics (KYMR) Turning Its Immunology Pipeline Into a Durable Platform Advantage? - Sahm
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) - Benzinga
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside - Finviz
Muted and missing M&As: JPM deals absent in 2026 - BioWorld MedTech
BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs - marketscreener.com
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - Investing News Network
Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones - TipRanks
Kymera Therapeutics (KYMR): Investor Outlook On Biotech's 59.75% Upside Potential - DirectorsTalk Interviews
Kymera Therapeutics Outlines 2026 Milestones, Advances Clinical Trials for Immunology Candidates - Quiver Quantitative
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewswire Inc.
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):